Of note, some immunomodulatory antibodies directed against CTLA-4 or CD137 also show promise for modulating self-directed immune responses in pre-clinical model systems but also in patients with autoimmune diseases, broadening the therapeutic value of this class of molecules beyond the treatment of cancer (4–6). This evidence concerns the gene TNFRSF9 and cancer.